KH176m
KH176m is the major active metabolite of KH176 (HY-121577). KH176m is a microsomal prostaglandin E synthase-1 (mPGES-1) inhibitor that can cross the blood-brain barrier, with an IC50 of 0.16 µM against mouse mPGES-1 and 1.51 µM against human mPGES-1. KH176m blocks LPS- or IL-1β-induced PGE2 production, scavenges ROS, inhibits lipid peroxidation, accelerates NADPH consumption, suppresses the growth of prostate cancer spheroids, reduces the CD44+ CD24− prostate cancer stem cell population, and protects fibroblasts with oxidative phosphorylation defects from redox stress-induced death. KH176m can be used in research related to mitochondrial diseases, inflammatory pain, inflammatory neurological diseases, inflammatory cancers, and prostate cancer.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- CAS No.: 2095304-61-1
- 화학식: C19H28N2O4
- 분자량:348.44
-
보관:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
제품 설명
IC50 & Target
[1]|
mmPGES-1 0.16 μM (IC50) |
hmPGES-1 1.51 μM (IC50) |
In Vitro
KH176m (1 μM; 24 h) selectively reduces elevated levels of PGE2, PGE1, and PGA2 in primary human dermal fibroblasts from patients with mitochondrial complex I deficiency, without altering levels of PGD2 or PGF2α[1].
KH176m (72 h) dose-dependently reduces PGE2 levels in primary human skin fibroblasts from patients with mitochondrial complex I deficiency, with an IC50 of 85.3 nM[1].
KH176m (24 h) dose-dependently and selectively inhibits LPS (HY-D1056)-induced PGE2 production in primary human dermal fibroblasts from healthy donors and RAW264.7 cells, with IC50 values of 92.9 nM and 0.56 nM, respectively, without altering PGD2 levels[1].
KH176m (24 h) dose-dependently and selectively inhibits IL-1β-induced PGE2 production in primary dermal fibroblasts from healthy humans, with an IC50 of 0.28 μM after 24 h of incubation, without altering the level of PGD2[1].
KH176m (15 min) inhibits the enzymatic activity of mPGES-1 in lipopolysaccharide (LPS)-stimulated mouse macrophage-like RAW264.7 cells and microsomes of healthy primary human dermal fibroblasts, with IC50 values of 0.16 μM and 1.51 μM, respectively[1].
KH176m (1-10 μM; 6-24 h) dose-dependently inhibits the expression of mPGES-1 protein and mRNA in LPS- and IL-1β-induced mouse macrophage-like RAW264.7 cells, without altering the expression of COX-2, mPGES-2, cPGES or COX-1[1].
KH176m (0.62-5 µM; 2 min injection, 4 min dissociation) binds directly to purified recombinant human Prdx2 with a KD value of 0.305 µM, whereas KH176 shows no dose-dependent binding to Prdx2[3].
KH176m (1-10 μM; 24 h) dose-dependently reduces the expression of constitutive mPGES-1 protein in two-dimensionally cultured DU145 human prostate cancer cells and induces a decrease in spheroid size[2].
KH176m (0.3-3 μM; 7 days) dose-dependently reduces the sphere size and mPGES-1 mRNA expression of CD44+ CD24− cancer stem cells isolated from DU145 human prostate cancer cells cultured in Matrigel or ultra-low attachment plates for 7 days[2].
KH176m (0.3-3 μM; 7 days) reduces the proportion of CD44+ CD24− cancer stem cells in Matrigel-cultured human prostate cancer DU145 spheroids in a dose-dependent manner[2].
KH176m (3.2-88 nM; 24 h) potently protects complex I-deficient P4 primary human skin fibroblasts and a variety of other oxidative phosphorylation (OXPHOS)-deficient primary human skin fibroblasts against BSO (HY-106376)-induced death, with an EC50 value as low as 3.2 nM[3].
KH176m (255 nM; 24 h) potently reduces ROS levels in complex I-deficient P4 primary human skin fibroblasts, with an IC50 of 255 nM[3].
KH176m (3 µM) effectively scavenges hydrogen peroxide and superoxide anion in complex I-deficient P4 primary human skin fibroblasts[3].
KH176m (24 h) potently reduces the basal cytoplasmic superoxide level in complex I-deficient P4 primary human skin fibroblasts, with an EC50 of 1.7 µM[3].
KH176m (30 min) potently inhibits cumene hydroperoxide-induced lipid peroxidation in complex I-deficient P4 primary human skin fibroblasts, with an IC50 of 0.71 µM[3].
KH176m (30 min) potently reduces mitochondrial superoxide levels in complex I-deficient P4 primary human skin fibroblasts, with an IC50 of 14 µM[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:LPS-stimulated mouse macrophage-like RAW264.7 cells
-
Concentration:1, 3, 10 μM
-
Incubation Time:6 h (LPS stimulation); 24 h (LPS stimulation)
-
Result:Dose-dependently reduced LPS-induced mPGES-1 expression at both protein and mRNA levels.
Left expression of COX-2, mPGES-2, cPGES, and COX-1 unchanged.
-
Cell Line:IL-1β-stimulated primary human skin fibroblasts (healthy controls) with exogenous PGE2 supplementation
-
Concentration:3 μM
-
Incubation Time:24 h
-
Result:Inhibited IL-1β-induced mPGES-1 protein and mRNA expression.
Had its inhibitory effect reversed by supplementation with exogenous PGE2.
-
Cell Line:human prostate cancer DU145 cell line (2D culture)
-
Concentration:1, 3, 10 μM
-
Incubation Time:24 h
-
Result:Reduced constitutive mPGES-1 protein expression in a dose-dependent manner.
Caused statistically significant reductions relative to vehicle at 3 μM and 10 μM.
Chemical Information
-
CAS No. 2095304-61-1
-
분자량 348.44
-
화학식 C19H28N2O4
-
SMILES
C(C[C@](C(N[C@@H]1CCCNC1)=O)(C)O)C2=C(C)C(=O)C(C)=C(C)C2=O
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocol
-
Kinase activity and phosphorylation assays
Kinase activity assays measure the ability of kinases to transfer phosphate groups from ATP to specific substrates, while phosphorylation assays detect the presence and levels of phosphorylated proteins. Common methods include radiolabeled ATP incorporation (e. g. ,), ADP release detection via bioluminescence (e. g. ,[3]), enzyme-linked immunosorbent assays (ELISA) for phospho-specific epitopes (e. g. ,[6]), and microtiter-based formats for high-throughput screening (e. g. ,[8]). The ADP-Glo assay quantifies kinase activity by measuring ADP produced during phosphorylation using a luciferase-based system. Radiometric assays involve autoradiography or scintillation counting after incorporation of 32P-labeled ATP into substrate proteins. ELISA-based approaches rely on phospho-specific antibodies to detect activated kinases in cell lysates or purified samples.
-
Western Blot
Western blotting (WB) is a commonly used experimental method in molecular biology, biochemistry, and immunogenetics for identifying and quantifying target proteins. It combines gel electrophoresis with immunoassay, enabling researchers to analyze protein expression, post-translational modifications, and molecular weight.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
ROS/oxidative-stress fluorescent staining
ROS/oxidative-stress fluorescent staining uses cell-permeant fluorogenic probes that become fluorescent after oxidation inside cells or tissues; commonly used examples include DCFH-DA/DCFDA for broad cellular oxidant detection, DHE for superoxide-related signal detection, MitoSOX for mitochondrial superoxide-related signal detection, and CellROX probes for oxidative-stress-associated fluorescence readouts. The assay detects probe oxidation rather than a single ROS species unless the probe and analysis method have been chemically validated for that species. DCFH-DA enters cells, is deacetylated by intracellular esterases to DCFH, and produces fluorescent DCF after oxidation, so the readout is used as an operational measure of total cellular oxidative stress rather than a species-specific ROS measurement. DHE and MitoSOX can report superoxide-related oxidation, but red fluorescence alone can include non-specific ethidium-like oxidation products; HPLC or optimized spectral approaches are
-
Formalin-Induced Paw Inflammation/Nociceptive Inflammation
The formalin-induced paw inflammation/nociceptive test is a chemical persistent pain model in rodents in which subcutaneous injection of formalin into the hind paw produces spontaneous nocifensive behaviors such as flinching and licking. The response is classically biphasic, consisting of an early acute phase (Phase I) reflecting direct activation of peripheral nociceptors (particularly C-fiber afferents), followed by a later prolonged phase (Phase II) associated with central sensitization in the spinal dorsal horn driven by sustained afferent input and inflammatory signaling. This model is widely used to evaluate analgesic and anti-inflammatory interventions because it captures both peripheral nociception and central sensitization processes within a single assay system.
-
Ferroptosis Solutions
Ferroptosis is an iron-dependent, non-apoptotic form of regulated cell death characterized by lethal lipid peroxidation and sensitivity to suppression by iron chelators or lipophilic radical-trapping antioxidants. The core pathway links cystine uptake through system Xc−, glutathione availability, GPX4-dependent detoxification of phospholipid hydroperoxides, iron-dependent oxidative reactions, and polyunsaturated-phospholipid metabolism into a cell-death program that is biochemically and morphologically distinct from apoptosis, necrosis, and autophagy. The ferroptosis pathway is experimentally linked to phenotype through chemical and genetic perturbation. Erastin induces ferroptosis by inhibiting cystine uptake through system Xc− and weakening antioxidant defenses, while GPX4 inhibition or depletion causes lipid peroxide accumulation and ferroptotic cancer-cell death. ACSL4 and oxidizable arachidonoyl- or adrenoyl-containing phosphatidylethanolamines shape ferroptosis sensitivity by con
-
Protocol for Kinase activity and phosphorylation assays
Kinase activity assays measure transfer of phosphate from ATP to a protein or peptide substrate, generating phosphorylated substrate, ADP, or incorporated radiolabeled phosphate as the readout; phosphorylation assays measure site-specific phosphorylation in cells or tissues as a proxy for kinase-pathway activation, inhibition, or substrate regulation. Phosphorylation can be detected by phospho-specific Western blot, immunoprecipitation kinase assay, phospho-immunofluorescence, phospho-flow cytometry, luminescent ADP detection, radiolabeled ATP incorporation, or reporter-based pathway assays, and these readouts can be applied to cancer cells, primary neurons, mouse tumors, organoids, inflammatory macrophages, ferroptosis studies, and mitophagy studies when the kinase target is biologically relevant.
-
Pyroptosis Solutions
Pyroptosis is a lytic inflammatory cell-death pathway executed by gasdermin pores, most classically through inflammasome-mediated activation of caspase-1, cleavage of gasdermin D, membrane pore formation, LDH release, and secretion of IL-1β and IL-18. The canonical pathway is commonly modeled by priming cells with an inflammatory signal such as LPS to induce pro-IL-1β and inflammasome components, followed by an activation signal such as ATP or nigericin to activate NLRP3, ASC speck formation, caspase-1 cleavage, GSDMD cleavage, cytokine release, and pyroptotic membrane rupture. The non-canonical pathway is triggered when cytosolic LPS activates mouse caspase-11 or human caspase-4/5, leading to GSDMD cleavage and pyroptosis, and this can secondarily activate NLRP3-dependent IL-1β release. Pyroptosis is linked to inflammatory injury, infection, cancer, liver disease, ocular disease, placental inflammation, and other disease phenotypes, but unresolved questions include which gasdermin fam
순도&문서
References
[1]. Jiang X, et al. Mechanism of action and potential applications of selective inhibition of microsomal prostaglandin E synthase-1-mediated PGE2 biosynthesis by sonlicromanol's metabolite KH176m. Sci Rep. 2021 Jan 13;11(1):880. [Content Brief]
[2]. Jiang X, et al. Sonlicromanol's active metabolite KH176m normalizes prostate cancer stem cell mPGES-1 overexpression and inhibits cancer spheroid growth. PloS one. 2021;16(7):e0254315. [Content Brief]
[3]. Beyrath J, et al. KH176 Safeguards Mitochondrial Diseased Cells from Redox Stress-Induced Cell Death by Interacting with the Thioredoxin System/Peroxiredoxin Enzyme Machinery. Scientific reports. 2018 Apr 26;8(1):6577. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Keywords
- KH176m
- 2095304-61-1
- PGE synthase
- Reactive Oxygen Species (ROS)
- microsomal prostaglandin E synthase-1
- DU145 human prostate cancer cells
- primary human skin fibroblasts
- LNCaP human prostate cancer cells
- prostate cancer stem cells
- mPGES-1
- RAW264.7 cells
- peroxiredoxin
- mitochondrial complex I-deficient patients
- reactive oxygen species
- Inhibitor
- inhibitor
- inhibit